# Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study

> **NCT01246479** · PHASE3 · COMPLETED · sponsor: **Valneva Austria GmbH** · enrollment: 23 (actual)

## Conditions studied

- Japanese Encephalitis

## Interventions

- **PROCEDURE:** Blood draw
- **BIOLOGICAL:** IC51 has given in the parent study IC51-322

## Key facts

- **NCT ID:** NCT01246479
- **Lead sponsor:** Valneva Austria GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-10
- **Final completion:** 2014-09
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2020-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01246479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01246479, "Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01246479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*